NCT03867175View on ClinicalTrials.gov

Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

April 21, 2025

Study Completion Date

April 21, 2025

Conditions
Metastatic Lung CancerStage IV Lung Cancer
Interventions
RADIATION

Stereotactic Body Radiation Therapy

Patients undergo 3-10 treatments of stereotactic body radiation therapy (SBRT)

BIOLOGICAL

Pembrolizumab

Patients undergo 3-10 treatments of SBRT. Patients also receive pembrolizumab IV over 30 minutes every 3-4 weeks for 1 year at the discretion of the treating physician.

Trial Locations (1)

27157

Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Wake Forest University Health Sciences

OTHER

NCT03867175 - Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter